An LC-ESI-MS/MS method for determination of ondansetron in low-volume plasma and cerebrospinal fluid: Method development, validation, and clinical application

Anna Siemiątkowska, Karen Frey, Katharine N. Gurba, Lara W. Crock, Simon Haroutounian, Leonid Kagan

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Ondansetron is used in clinical settings as an antiemetic drug. Although the animal studies showed its potential effectiveness also in treating neuropathic pain, the results from humans are inconclusive. The lack of efficacy of ondansetron in a subset of patients might be due to the overexpression of P-glycoprotein, which could result in low concentrations of ondansetron in the central nervous system (CNS). A surrogate of the CNS exposure might be drug concentration in the cerebrospinal fluid (CSF), especially in humans, as assessing the drug disposition directly in the patient's brain would be challenging. The study aimed to develop a sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to determine concentrations of ondansetron in human K3EDTA plasma and CSF. Ondansetron was extracted from biological matrices by liquid-liquid extraction. The quantification was performed on a Sciex QTRAP 6500+ mass spectrometer with labeled ondansetron as an internal standard. The calibration range was 0.25–350 ng/mL in plasma and 0.025–100 ng/mL in CSF; for both matrices, 25 µL of samples was required for the assays. The method was validated according to the FDA and EMA guidelines and showed acceptable results. A pilot study confirmed its suitability for clinical samples: after 4–16 mg of intravenous ondansetron, the determined concentrations in plasma were 1.22–235.90 ng/mL, while in CSF - 0.018–11.93 ng/mL. In conclusion, the developed method fulfilled all validation requirements and can be applied to pharmacokinetic studies assessing the CNS ondansetron exposure in humans. The method's advantages, such as a low volume of matrix and a wide calibration range, support its use in a study in which rich sampling and various drug doses are expected.

Original languageEnglish
Article number115625
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume235
DOIs
StatePublished - Oct 25 2023

Keywords

  • 5-HT3 receptor antagonist
  • Assay validation
  • Blank matrices
  • Carry-over
  • Methods comparison
  • P-glycoprotein

Fingerprint

Dive into the research topics of 'An LC-ESI-MS/MS method for determination of ondansetron in low-volume plasma and cerebrospinal fluid: Method development, validation, and clinical application'. Together they form a unique fingerprint.

Cite this